The Adenosinergic System : A Non-Dopaminergic Target in Parkinson’s Disease /

Detalles Bibliográficos
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Morelli, Micaela. (Editor ), Simola, Nicola. (Editor ), Wardas, Jadwiga. (Editor )
Formato: eBook
Lenguaje:English
Publicado: Cham : Springer International Publishing : Imprint: Springer, 2015.
Edición:1st ed. 2015.
Colección:Current Topics in Neurotoxicity, 10
Materias:
LEADER 02389nam a22003255i 4500
001 000294470
005 20211110183838.0
007 cr nn 008mamaa
008 150907s2015 gw | s |||| 0|eng d
020 |a 9783319202730 
024 7 |a 10.1007/978-3-319-20273-0  |2 doi 
040 |a Sistema de Bibliotecas del Tecnológico de Costa Rica 
245 1 4 |a The Adenosinergic System :  |b A Non-Dopaminergic Target in Parkinson’s Disease /  |c edited by Micaela Morelli, Nicola Simola, Jadwiga Wardas. 
250 |a 1st ed. 2015. 
260 # # |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2015. 
300 |a XII, 337 p. 41 illus., 31 illus. in color. :  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Current Topics in Neurotoxicity,  |v 10 
505 0 |a Adenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation – relevance for Parkinson’s disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson’s disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson’s disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline – the first approved A2A antagonist for the treatment of Parkinson’s disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia. 
650 0 |a Neurosciences. 
650 0 |a Neurology . 
650 1 4 |a Neurosciences. 
650 2 4 |a Neurology. 
700 1 |a Morelli, Micaela.  |e editor. 
700 1 |a Simola, Nicola.  |e editor. 
700 1 |a Wardas, Jadwiga.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks